TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

Benzinga Logo Benzinga • •By Business Wire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly making false and misleading statements about its drug candidate sonelokimab, which led to a significant stock price drop after disappointing Phase 3 trial results.

Insights
AMAT   neutral

Reporting Q4 results with no explicit positive or negative pre-announcement signals


MLTX   negative

The company is accused of misleading investors about its drug candidate's effectiveness, resulting in a nearly 90% stock value loss and potential legal action